Skip to main content
SpringerLink
Log in

The Evolution of Therapy for Acute Lymphatic Leukemia in Children

  • Chapter
Biology and Therapy of Acute Leukemia

Part of the book series: Developments in Oncology ((DION,volume 33))

  • 35 Accesses

Abstract

In 1948, Dr. Farber and his colleagues (1) used the first effective antileukemic agent, aminopterin, to treat children with acute lymphatic leukemia. In many of the subsequent studies over the next decade, single agents were used to induce a remission and therapy was then stopped until there was recurrence of the disease (Table I). The most effective single agents were prednisone and vincristine which induced remission in 60% to 70% of the children.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Farber S, Diamond et al: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-amino-pteroyl-glutamic acid (aminopterin). N. Eng. J. Med. 238: 787–793, 1948.

    Article  CAS  Google Scholar 

  2. Freireich EJ, Gehan E, Frei E III et al: The effect of 6-mercaptopurine on the duration of steroid-induced remission in acute leukemia: A model for evaluation of other potentially useful therapy. Blood 21: 699–716, 1963.

    CAS  Google Scholar 

  3. Hyman CB, Borda E et al: Prednisone in childhood leukemia; comparison of interrupted and continuous therapy. Pediatrics 24: 1005–1008, 1959.

    PubMed  CAS  Google Scholar 

  4. Vietti TJ, Sullivan MP, Berry DH et al: The response of acute childhood leukemia to an initial and a second course of prednisone. J. Pediatr. 66: 18–26, 1965.

    Article  PubMed  CAS  Google Scholar 

  5. Wolff JA, Brubaker CA, Murphy ML et al: Prednisone therapy of acute childhood leukemia: Prognosis and duration of response in 330 treated patients. J. Pediatr. 70: 626–631, 1967.

    Article  PubMed  CAS  Google Scholar 

  6. Evans AE, Farber S, Brunet S, Mariano PJ: Vincristine in the treatment of acute leukemia in children. Cancer 16: 1302–1306, 1963.

    Article  PubMed  CAS  Google Scholar 

  7. Haggard ME, Fernbach DJ, Holcomb TM et al: Vincristine in acute leukemia of childhood. Cancer 22: 438–444, 1968.

    Article  PubMed  CAS  Google Scholar 

  8. Heyn RM, Beatty EC Jr, Hammond D et al: Vincristine in the treatment of acute leukemia. Pediatrics 38: 82–91, 1966.

    PubMed  CAS  Google Scholar 

  9. Karon M, Freireich EJ, Frei E III et al: The role of vincristine in the treatment of childhood acute leukemia. Clin. Pharmacol. Ther. 7: 332–339, 1966.

    PubMed  CAS  Google Scholar 

  10. Ertel IJ, Nesbit MG, Hammond D et al: Effective dose of L-asparaginase for induction of remission in previously treated children with acute leukemia: A report from Children’s Cancer Study Group. Cancer Res. 39: 3893–3896, 1979.

    PubMed  CAS  Google Scholar 

  11. Sutow WW, Garcia F, Starling KA et al: L-asparaginase therapy in children with advanced leukemia. Cancer 28: 819–824, 1971.

    Article  PubMed  CAS  Google Scholar 

  12. Fernbach DJ, Sutow WW, Thurman WG, Vietti TJ: Clinical evaluation of cyclophosphamide, a new agent for the treatment of children with acute leukemia. JAMA 182: 30–37, 1962.

    PubMed  CAS  Google Scholar 

  13. Holcomb TM: Cyclophosphamide (NSC-26271) in the treatment of acute leukemia in children. Cancer Chemother. Rep. 51: 389–392, 1967.

    Google Scholar 

  14. Pierce MI, Shore N, Sitarz A et al: Cyclophosphamide therapy in acute leukemia of childhood. Cancer 19: 1551–1560, 1966.

    Article  PubMed  CAS  Google Scholar 

  15. Holton CP, Lonsdale D, Nora AH et al: Clinical study of daunomycin (NSC-82151) in children with acute leukemia. Cancer 22: 1014–1017, 1968.

    Article  PubMed  CAS  Google Scholar 

  16. Jones B, Holland JF, Morrison AR: Daunomycin in the treatment of resistant acute lymphoblastic leukemia. Cancer Res. 31: 84–90, 1971.

    PubMed  CAS  Google Scholar 

  17. Tan C, Tasaka H, Yu KP et al: Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Cancer 20: 333–353, 1967.

    Article  PubMed  CAS  Google Scholar 

  18. Ragab AH, Sutow WW, Komp DM, Starling KA, Lyon GM, George S: Adriamycin in the treatment of childhood acute leukemia. Cancer 36: 1123–1126, 1975.

    Google Scholar 

  19. Starling KA, Berry DH, Britton HA, Humphrey GB, Vats T, Ragab AH: Three dose regimens of adriamycin for induction of remission in acute leukemia in children. Med. Pediatr. Onc. 1: 271–276, 1975.

    Article  CAS  Google Scholar 

  20. Tan C, Rosen G, Charini F, Haghbin M, Helson L, Wollner N, Murphy ML: Adriamycin (NSC-123127) in pediatric malignancies. Cancer Chemother. Rep. 6: 259–266, 1975.

    Google Scholar 

  21. Boggs D, Wintrobe MW, Cartwright GE: The acute leukemias. Medicine 41: 163–225, 1962.

    Article  PubMed  CAS  Google Scholar 

  22. Frei E III, Freireich EJ, Gehan E et al: (Acute Leukemia Cooperative Group B): Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate, from the Acute Leukemia Group B. Blood 18: 431–454, 1961.

    Google Scholar 

  23. Sullivan MP, Beatty EC Jr, Hyman CB et al: A comparison of the effectiveness of standard dose 6-mercaptopurine, combination 6-mercaptopurine and DON, and high-loading 6-mercaptopurine therapies in treatment of the acute leukemias of childhood: Results of a cooperative study. Cancer Chemother. Rep. 18: 83–95, 1962.

    PubMed  CAS  Google Scholar 

  24. Holland JF: Symposium on the experimental pharmacology and clinical use of antimetabolites. VIII. Folic acid antagonists. Clin. Pharmacol. Ther. 2: 374–409, 1961.

    PubMed  CAS  Google Scholar 

  25. Howard JP, Albo V, Newton WA Jr: Cytosine arabinoside results of a cooperative study in acute childhood leukemia. Cancer 21: 341–345, 1968.

    Article  PubMed  CAS  Google Scholar 

  26. Traggis DG, Dohlwitz A, Das L, Jaffe N, Moloney WC, Hall TC: Cytosine arabinoside in acute leukemia of childhood. Cancer 28: 815–818, 1971.

    Article  PubMed  CAS  Google Scholar 

  27. Wang JJ, Selawry OS, Bodey GP, Vietti TJ: Prolonged infusion of arabinosyl cytosine in childhood leukemia. Cancer 25: 1–6, 1970.

    Article  PubMed  CAS  Google Scholar 

  28. Fernbach DJ, Griffith KM, Haggard ME et al: Chemotherapy of acute leukemia in childhood: Comparison of cyclophosphamide and mercaptopurine. N. Eng. J. Med. 275: 451–456, 1966.

    Article  CAS  Google Scholar 

  29. Lonsdale D, Gehan EA, Fernbach DJ et al: Interrupted vs. continued maintenance therapy in childhood acute leukemia. Cancer 36: 341–352, 1975.

    Article  PubMed  CAS  Google Scholar 

  30. Fernbach DJ, George SL, Sutow WW et al: Long-term results of reinforcement therapy in children with acute leukemia. Cancer 36: 1552–1559, 1975.

    Article  PubMed  CAS  Google Scholar 

  31. Krivit W, Brubaker C, Thatcher LG et al: Maintenance therapy in acute leukemia of children. Comparison of cyclic vs. sequential methods. Cancer 21: 352–356, 1968.

    Article  PubMed  CAS  Google Scholar 

  32. Zuelzer WW: Implications of long-term survival in acute leukemia of childhood treated with composite cyclic therapy. Blood 24: 477–494, 1964.

    PubMed  CAS  Google Scholar 

  33. Berry DH, Pullen J, George S, Vietti TJ, Sullivan MP, Fernbach D: Comparison of prednisone, vincristine, methotrexate and 6-mercaptopurine versus vincristine and prednisone induction therapy in childhood acute leukemia. Cancer 36: 98–102, 1975.

    Article  PubMed  CAS  Google Scholar 

  34. Komp DM, George SL, Falletta JM et al: Cyclophosphamideasparaginase-vincristine-prednisone induction therapy in childhood acute lymphocytic and non-lymphocytic leukemia. Cancer 37: 1243–1247, 1976.

    Article  PubMed  CAS  Google Scholar 

  35. Pinkel D: The treatment of childhood acute lymphocytic leukemia. In: Modern Trends in Human Leukemia III, Neth R, Gallo RC, Hofschneider P-H et al (eds), Berlin, Springer-Verlag, 1979, p. 81.

    Google Scholar 

  36. Holton CP, Vietti TJ, Nora AH et al: Daunomycin and prednisone for induction of remission in advanced leukemia. N. Engl. J. Med. 280: 171–174, 1969.

    Article  PubMed  CAS  Google Scholar 

  37. Sackman-Muriel F, Svarch E, Helft ME et al: Evaluation of intensification and maintenance programs in the treatment of acute lymphoblastic leukemia. Cancer 42: 1730–1740, 1978.

    Article  Google Scholar 

  38. Jacquillat C, Weil M, Gemon MF et al: Combination therapy in 130 patients with acute lymphoblastic leukemia (Protocol 06 LA 66-Paris). Cancer Res. 33: 3278–3284, 1973.

    PubMed  CAS  Google Scholar 

  39. Pavlovsky S, Penalver J, Epping-Helft M et al: Induction and maintenance of remission in acute leukemia. Effectiveness of combination therapy in 227 cases. Cancer 31: 273–279, 1973.

    Article  PubMed  CAS  Google Scholar 

  40. Vietti TJ, Starling K, Wilber K, Lonsdale D, Lane DM: Vincristine, prednisone and daunomycin in acute leukemia of childhood. Cancer 27: 602–607, 1971.

    Article  PubMed  CAS  Google Scholar 

  41. Aur RJA, Simone JV, Verzosa MS et al: Childhood acute lymphocytic leukemia: Study VIII. Cancer 42: 21–23, 1978.

    Article  Google Scholar 

  42. Jones B, Holland JF, Jacquillat C et al: Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. Med. Pediatr. Oncol. 3: 387–400, 1977.

    Article  PubMed  CAS  Google Scholar 

  43. Ortega JA, Nesbit ME Jr, Donaldson MH et al: L-asparaginase, vincristine and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res. 37: 535–540, 1977.

    PubMed  CAS  Google Scholar 

  44. Henze G, Langermann et al: Evgebuisse der studie BFM 76/79 zur behandlung der akutsu lymphoblastischen leukamie bei kindern and jugendlochen. Klin. Padiatr. 193: 145–154, 1981.

    Article  PubMed  CAS  Google Scholar 

  45. Riehm H, Gadner H et al: Acute lymphoblastic leukemia: Treatment results in three BFM studies (1970–1981). In: Leukemia Research: Advances in Cell Biology and Treatment, Murphy S, Gilbert JR (eds), Elsevier Science Publ. Co. Inc., 1983, pp. 251–263.

    Google Scholar 

  46. Fernbach DJ, Donaldson M, Lane D, Lonsdale D, Vietti TJ: The treatment of advanced acute leukemia in children with concomitant vincristine sulfate and cyclophosphamide. In: Proceedings of the Twelfth International Society of Hematology, Jaffe ER (ed), New York, 1968, p. 8.

    Google Scholar 

  47. Frei E III, Karon M, Levin RH et al: The effectiveness of combinations of antileukemia agents in inducing and maintaining remission in children with acute leukemia. Blood 26: 642–656, 1965.

    PubMed  Google Scholar 

  48. Skipper HE, Schabel FM Jr, Wilcox WS: Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother. Rep. 35: 1–111, 1964.

    PubMed  CAS  Google Scholar 

  49. Selawry OS (for Acute Leukemia Cooperative Group B): New treatment schedule with improved survival in childhood leukemia: Intermittent parenteral vs. daily oral methotrexate for maintenance of induced remission. JAMA 194: 75–81, 1965.

    Article  Google Scholar 

  50. Nagao T, Lampkin BC, Mauer AM: Maintenance therapy in acute childhood leukemia. J. Pediatr. 76: 134–137, 1970.

    Article  PubMed  CAS  Google Scholar 

  51. Holland JF, Glidewell 0: Complementary chemotherapy in acute leukemia. In: Recent Results in Cancer Research: Advances in the Treatment of Acute (Blastic) Leukemias, Mathe G (ed), New York, Springer-Verlag New York, Inc., 1970.

    Google Scholar 

  52. Australian Cancer Society’s Childhood Leukemia Study Group Cyclic drug regimen for acute childhood leukemia. Lancet 1: 313–318, 1968.

    Google Scholar 

  53. Goldin A, Venditti JM, Humphreys SR et al: Modification of treatment schedules in the management of advanced mouse leukemia with amethopterin. J. Nat. Cancer Inst. 17: 203–212, 1956.

    PubMed  CAS  Google Scholar 

  54. Lewis B: Somatic Cell Mutants in Gene Expression, 2nd Ed., Lewis B (ed), John Wiley and Sons, New York, pp. 142–188.

    Google Scholar 

  55. Mauer AM: Cell kinetics and practical consequences for therapy of acute leukemia. N. Eng. J. Med. 293: 389–393, 1975.

    Article  Google Scholar 

  56. Saunders EF, Lampkin BC, Mauer AM: Variation of proliferating activity in leukemia cell populations of patients with acute leukemia. J. Clin. Invest. 46: 1356–1363, 1967

    Article  PubMed  CAS  Google Scholar 

  57. Gavosto F, Pileri A, Gabutti V et al: Unusual blast proliferation and kinetics in acute lymphoblastic leukaemia. Europ. J. Cancer 5: 343–348, 1969.

    CAS  Google Scholar 

  58. Gavosto F, Pileri A, Peforaso L: Proliferative kinetics of acute leukemia cells in relation to the chemotherapy. Acta. Genet. Med. Gemellol. 17: 30, 1968.

    PubMed  CAS  Google Scholar 

  59. Karle H, Ernst P, Killman S: Changing cytokinetic patterns of human leukaemic lymphoblasts during the course of the disease, studied in vivo. Br. J. Haemat. 24: 231–244, 1973.

    Article  CAS  Google Scholar 

  60. Steel GG: Cell population kinetics of human tumors. In: Growth Kinetics of Tumors, Steel GG (ed), Clarendon Press, 1977, pp. 185–216.

    Google Scholar 

  61. Wagner HP, Cottier H, Cronletie EP: Variability of proliferative patterns in acute lymphoid leukemia of children. Blood 39: 176–186, 1972.

    PubMed  CAS  Google Scholar 

  62. Edelstein M, Valeriote F, Vietti T: Influence of continuous infusion of cytosine arabinoside on sequencing with daunorubicin in L1210 leukemia. Cancer Treat. Rep. 62: 547–548, 1978.

    PubMed  CAS  Google Scholar 

  63. Pinkel D: Treatment of acute leukemia. Pediatr. Clin. North Am. 23: 117–130, 1976.

    PubMed  CAS  Google Scholar 

  64. Schabel FM Jr: In vivo leukemic cell kill kinetics and “curability” in expe it mental systems. In: The Proliferation and Spread of Neoplastic Cells, Baltimore, The Williams & Wilkins Co., 1968, pp. 379–408.

    Google Scholar 

  65. Skipper HE: Cellular kinetics associated with curability of experimental leukemias. In: Perspectives of Experimental Leukemias, Dameshek W, Dutcher RM (eds), New York, Grave and Stratton, Inc., 1968, pp. 187–215.

    Google Scholar 

  66. Skipper HE, Schabel FM et al: Implications of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother. Rep. 54: 431–450, 1970.

    PubMed  CAS  Google Scholar 

  67. Pinkel D: Patterns of failure in acute lymphocytic leukemia. Cancer Treat. Symp. 2: 259–266, 1983.

    Google Scholar 

  68. Freireich EJ, Henderson ES, Karon MR, Frei E III: The treatment of acute leukemia considered with respect to cell population kinetics. In: Proliferation and Spread of Neoplastic Cells, Baltimore, The Williams & Wilkins Co., 1968, pp. 441–452.

    Google Scholar 

  69. Henderson ES: Combination chemotherapy of acute lymphocytic leukemia of childhood. Cancer Res. 27: 2570–2572, 1967.

    PubMed  CAS  Google Scholar 

  70. George SL, Fernbach DJ, Vietti TJ et al: Factors influencing survival in pediatric acute leukemia: The SWCCSG Experience, 1958–1970. Cancer 32: 1542–1553, 1973.

    Article  PubMed  CAS  Google Scholar 

  71. Evans AE: Central nervous system involvement in children with acute leukemia. Cancer 17: 256–258, 1963.

    Article  Google Scholar 

  72. Kuo AH-M, Yatagonas X, Galicich JH, Fried J, Clarkson BD: Proliferative kinetics of central nervous system (CNS) leukemia. Cancer 36: 232–239, 1975.

    Article  PubMed  CAS  Google Scholar 

  73. Tsuchiya J, Mofelel M, Shimano S et al: Proliferative kinetics of the leukemia cells in meningeal leukemia. Cancer 42: 1255–1262, 1978.

    Article  PubMed  CAS  Google Scholar 

  74. Johnson R: An experimental therapeutic approach to L1210 leuekmia in mice: Combination chemotherapy and central nervous system irradiation. J. Natl. Cancer Inst. 32: 1333–1341, 1964.

    PubMed  CAS  Google Scholar 

  75. Simone JV: Factors that influence haematological remission duration in acute lymphocytic leukemia. Br. J. Haem. 32: 461–468, 1976.

    Article  Google Scholar 

  76. Simone JV, Aur RJA, Hustu HO et al: Combined modality therapy of acute lymphocytic leukemia. Cancer 35: 25–35, 1975.

    Article  PubMed  CAS  Google Scholar 

  77. Simone JV, Aur RJA, Hustu HO et al: Three to ten years after cessation of therapy in children with leukemia. Cancer 42: 839–844, 1978.

    Article  PubMed  CAS  Google Scholar 

  78. Simone JV: Acute lymphocytic leukemia in childhood. Seminars in Hematology 11: 25–39, 1974.

    PubMed  CAS  Google Scholar 

  79. Haghbin M, Murphy ML, Tan CC et al: A long term clinical followup of children with acute lymphoblastic leukemia treated with intensive chemotherapy regimens. Cancer 46: 241–252, 1980.

    Article  PubMed  CAS  Google Scholar 

  80. Haghbin M: Chemotherapy of acute lymphoblastic leukemia in children. Am. J. Hematol. 1: 201–209, 1976.

    Article  PubMed  CAS  Google Scholar 

  81. Haghbin M, Tan CC, Clarkson BD, Mike V, Burchenal JH, Murphy ML: Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol). Cancer 33: 1491–1498, 1974.

    Article  PubMed  CAS  Google Scholar 

  82. Haghbin M, Tan CTC, Clarkson BD, Mike V et al: Treatment of acute lymphoblastic leukemia in children with “prophylactic” intrathecal methotrexate and intensive systemic chemotherapy. Caner Res. 35: 807–811, 1975.

    CAS  Google Scholar 

  83. Sullivan MP, Chen T, Dyment PG et al: Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: A Pediatric Oncology Group Study. Blood 60: 948–958, 1982.

    PubMed  CAS  Google Scholar 

  84. Freeman AI, Brecher ML, Wang JJ et al: Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukemia (ALL). In: Modern Trends in Human Leukemia III, Neth R, Gallo RC, Hofschneider P-H et al (eds), Berlin, Springer-Verlag, 1979, p. 115.

    Google Scholar 

  85. Freeman AI, Weinberg V, Brecher ML et al: Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. NEJM 308: 477–484, 1983.

    Article  PubMed  CAS  Google Scholar 

  86. Green DM, Brecher ML, Blumenson LE et al: The use of intermediate dose methotrexate in increased risk childhood acute lymphoblastic leukemia: A comparison of three versus six courses. Cancer 50: 2722–2727, 1982.

    Article  PubMed  CAS  Google Scholar 

  87. Nesbit ME, Sather H, Robison LL et al: Sanctuary therapy: A randomized trial of 724 children with previously untreated acute lymphoblastic leukemia: A report from the Children’s Cancer Study Group. Cancer Res. 42: 674–680, 1982.

    PubMed  CAS  Google Scholar 

  88. Nesbit ME, Sather HN et al: Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukemias: Comparison of 1800 rad and 2400 rad. A report from the Children’s Cancer Study Group. Lancet 1: 461–465, 1981.

    Article  PubMed  Google Scholar 

  89. Sallan SE, Hitchcock S et al: Influence of intensive asparaginase in the treatment of childhood non T-cell acute lymphoblastic leukemia. Cancer Res. 43: 5601–5607, 1983.

    PubMed  CAS  Google Scholar 

  90. Capizzi RL: Schedule dependent synergism and antagonism between methotrexate and L-asparaginase. Biochem. Pharmacol. 23: 151–162, 1974.

    Google Scholar 

  91. Krance R, Newman D et al: Intermediate dose methotrexate and arabinosyl cytosine in combination therapy of childhood acute lymphocytic leukemia. Proc. Amer. Assoc. Clin. Oncol. 20: 201, 1984.

    Google Scholar 

  92. Amadori S, Papa G, Avvisati G et al: Sequential combination of systemic high-dose Ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma. J. Clin. Oncol. 2: 98–101, 1984.

    PubMed  CAS  Google Scholar 

  93. Zim S, Johnson CE, Chabner BA, Poplack DG: Cellular pharmacokinetics of 6-mercaptopurine in human leukemia and lymphoma cells. Proc. of Amer. Assoc. Cancer Res. 25: 349, 1984.

    Google Scholar 

  94. Willoughby MLN: Treatment of overt meningeal leukemia in children: Results of second MRC meningeal leukemia trial. Br. Med. J. 1: 864–867, 1976.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Teresa J. Vietti M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Boyett Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Wayne State University, Detroit, Michigan, USA

    Laurence Baker , Frederick Valeriote  & Voravit Ratanatharathorn ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishing, Boston

About this chapter

Cite this chapter

Vietti, T.J., Boyett, J. (1985). The Evolution of Therapy for Acute Lymphatic Leukemia in Children. In: Baker, L., Valeriote, F., Ratanatharathorn, V. (eds) Biology and Therapy of Acute Leukemia. Developments in Oncology, vol 33. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2609-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2609-0_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9633-1

  • Online ISBN: 978-1-4613-2609-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation